Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

ABSTRACT: The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.

DISEASE(S): Endometrial Cancer,Lung Cancer,Colorectal Cancer (crc),Colorectal Cancer,Pancreatic Cancer,Non-small Cell Lung Cancer (nsclc),Lung Neoplasms,Neoplasms,Pancreatic Ductal Adenocarcinoma,Ovarian Cancer,Nsclc,Colon Cancer,Gastric Cancer,Non-small Cell Lung Cancer,Advanced Solid Tumor,Colorectal Neoplasms,Esophageal Cancer,Carcinoma, Non-small-cell Lung,Colonic Neoplasms

PROVIDER: 2742064 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR